Clinical Trial Update: Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of pegfilgrastim and rituximab in patients with untreated, relapsed, or refractory follicular lymphoma, small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma
• Mucosa-associated Lymphoid Tissue Lymphoma
• Nodal Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma
• Splenic Marginal Zone Lymphoma

Drugs mentioned

• Pegfilgrastim (pegfilgrastim)
• Rituximab (rituximab)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-10-09